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ABSTRACT  
 
Background: Genome-wide association studies (GWAS) have identified several loci 
associated with schizophrenia and/or bipolar disorder. We performed a GWAS of 
psychosis, as a broad syndrome, rather than within specific diagnostic categories.  
Methods: 1,239 cases with schizophrenia, schizoaffective or psychotic bipolar disorder, 
857 of their unaffected relatives and 2,739 healthy controls were genotyped with the 
Affymetrix 6.0 SNP array. Analyses of 695,193 SNPs were conducted using UNPHASED, 
which combines information across families and unrelated individuals. We attempted to 
replicate signals we found in 23 genomic regions using existing data on non-overlapping 
samples from the Psychiatric GWAS Consortium (PGC) and SGENE-plus cohorts (10,352 
schizophrenia patients and 24,474 controls).  
Results: No individual SNP showed compelling evidence for association with psychosis in 
our data. However, we observed a trend for association with same risk alleles at loci 
previously associated with schizophrenia (one-sided P=0.003).  A polygenic score 
analysis found that the PGC’s panel of SNPs associated with schizophrenia significantly 
predicted disease status in our sample (P=5x10-14) and explained approximately 2% of 
the phenotypic variance. 
Conclusion: Although narrowly-defined phenotypes have their advantages, we believe 
new loci may also be discovered through meta-analysis across broad phenotypes. The 
novel statistical methodology we introduced to model effect size heterogeneity 
between studies should help future GWAS that combine association evidence from 
related phenotypes. By applying these approaches we highlight three loci that warrant 
further investigation. We found that SNPs conveying risk for schizophrenia are also 
predictive of disease status in our data. 
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INTRODUCTION 
 
Psychotic disorders including schizophrenia, bipolar and schizoaffective disorders affect 
approximately 3% of the general population (1-6) and constitute the most severe forms 
of mental diseases. Characteristic symptoms include hallucinations, delusional beliefs as 
well as severe mood variations and cognitive impairments, all of which can lead to 
major changes in behaviour and ability to function. According to the WHO's World 
Health Report, these psychotic disorders are ranked within the top seven leading causes 
of disability in young adults (7).  
 
The genetic architecture of schizophrenia and bipolar disorder has been shown to 
include common alleles of subtle effect and rare mutations of large effect, often 
involving genome copy number variation (8-11). Recent large-scale meta-analyses of 
schizophrenia (12), conducted by the Psychiatric GWAS Consortium (PGC) combined 
data from over 50,000 individuals from 17 international cohorts (13-25) and identified 
seven associated loci. Of these loci, five were new and the remaining two had been 
previously implicated. The strongest new finding in schizophrenia was within an intron 
of a putative primary transcript for MIR137 (microRNA 137), a known regulator of 
neuronal development. Four other schizophrenia loci with strong statistical support 
contain predicted targets of MIR137, suggesting MIR137-mediated dysregulation as a 
previously unknown etiologic mechanism in schizophrenia. The meta-analysis (12) also 
confirmed the role of the major histocompatibility complex (MHC) region, as suggested 
in other studies (23, 24, 26, 27), as well as a marker in intron four of transcription factor 
4 (TCF4) (24). 
 
The PGC conducted a similar meta-analysis for bipolar disorder (28) including over 
11,000 cases and 51,000 controls from previous association studies (15, 29-41). The 
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analysis confirmed an association with CACNA1C and identified a new intronic variant in 
ODZ4. An overlap in the polygenic component between schizophrenia and bipolar 
disorder was also found (42, 43). In a combined meta-analysis of both schizophrenia and 
bipolar disorder, three loci reached genome-wide significance: CACNA1C, ANK3 and the 
ITIH3-ITIH4 region (28). 
 
As data accumulate, there is increasing evidence for overlap in the genetic component 
to risk between different psychiatric disorders (44-46). When combined with 
epidemiological and neuroimaging data (47-50), the shared genetic architecture 
supports the view of schizophrenia, bipolar disorder and other psychoses as related 
rather than aetiologically distinct entities (8, 12, 28, 46, 51-60). Motivated by these 
findings, we performed a GWAS of psychotic disorders including patients with 
schizophrenia, schizoaffective disorder and bipolar disorder with a history of psychotic 
symptoms.  
 
METHODS AND MATERIALS 
 
The cohort 
Prior to any exclusion, the full dataset included 6,935 participants with 1,820 patients, 
1,224 of their unaffected relatives and 3,891 healthy controls. These samples were 
collected through seven centres across Australia and Europe (Germany, Holland, Spain 
and UK). Participants provided written informed consent and the study was approved by 
the respective ethical committees at each of the seven participating centres. After 
quality control, the full sample included 4,835 participants of which 1,239, 857 and 
2,739 were patients, their unaffected relatives and healthy controls, respectively. 
Further sample and centre details are provided in Supplementary Table 1. 
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Inclusion and exclusion criteria and phenotype definition 
To allow for a DSM-IV (61) diagnosis to be ascertained or ruled out, all participants 
(including controls and unaffected family members) underwent a structured clinical 
interview with either the Schedule for Affective Disorders and Schizophrenia (SADS) or 
the Structured Clinical Interview for DSM Disorders (SCID) or the Schedules for Clinical 
Assessment in Neuropsychiatry (SCAN) (62-64). Of the cases passing quality control, 784 
met criteria for schizophrenia, 113 for bipolar disorder with a history of psychotic 
symptoms, 110 for psychotic disorder not otherwise specified, 97 for schizophreniform 
disorder, 64 for schizoaffective disorder, 44 for brief psychotic disorder, 20 for 
delusional disorder and 7 for substance-induced psychosis. Participants in all groups 
were excluded if they had a history of neurological disease or head injury resulting in 
loss of consciousness.  
 
DNA sample preparation 
Genomic DNA obtained from blood for all participants was sent to the Wellcome Trust 
Sanger Institute (WTSI), Cambridge, UK. Samples were processed in 96-well plate format 
and each plate carried a positive and a negative control. DNA concentrations were 
quantified using a PicoGreen assay (Invitrogen) and an aliquot assayed by agarose gel 
electrophoresis. A sample passed quality control if the original DNA concentration was 
at least 50 ng/µl and the DNA was not degraded.  
 
Genotyping methodology and quality control  
In order to track sample identity, 30 SNPs including sex chromosome markers, were 
typed on the Sequenom platform prior to entry to the whole genome genotyping 
pipeline. Of the initial 6,935 samples, 347 failed quality control due to degraded or 
insufficient DNA or incorrect sex classification. The remaining samples were sent for 
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genotyping with the Genome-wide Human SNP Array 6.0 at Affymetrix Services Lab 
(http://www.affymetrix.com).  
 
Data quality control (Supplementary Tables 2 & 3) 
Genotype calling was conducted using the CHIAMO algorithm (65, 66) modified for use 
with the Affymetrix 6.0 genotyping array. We excluded 11,610 SNPs with a study-wide 
missing data rate over 5%. We removed 26,858 SNPs with four or more Mendelian 
inheritance errors identified with Pedstats (67). Further exclusion criteria were 
departure from Hardy-Weinberg equilibrium (P<10-6) or minor allele frequency (MAF) 
less than 0.02 with 2,404 and 145,097 SNPs removed, respectively. A total of 38,895 
SNPs from the X or Y chromosomes or mitochondrial DNA were also excluded from the 
analysis. Finally, 9,499 poorly genotyped SNPs were removed following visual inspection 
of the genotyping intensity plots in the program Evoker (68).  
 
We excluded 214 samples with more than 2% missing data across all SNPs. Another 70 
samples were excluded due to divergent genome-wide heterozygosity (inbreeding 
coefficients were F > 0.076 or F < -0.076 as estimated with PLINK (42). Chromosomal 
sharing was inferred from a genome-wide subset of 71,677 SNPs and from each 
duplicate pair the sample with the most complete genotype data was kept. We removed 
70 duplicates and monozygotic twins by excluding one of each pair of individuals 
showing identity by descent greater than 95%.  
 
After quality control, 4,835 individuals remained. Initial analysis of the genotype data 
identified a high fraction of samples (approximately 30%), which showed very poor 
signal to noise ratio in the genotyping assay. As the experimental source of the problem 
was unclear, and to ensure a robust set of genotype calls, these samples were removed 
from further analysis. We note that the sample loss was randomly distributed across the 
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three clinical groups (32% of patients, 30% of relatives and 30% of controls; Chi square 
(2df) =3.2; P =0.20). Full details on the sample quality control are provided in 
Supplementary Table 2. 
 
In addition to 3,490 unrelated individuals, there were 1,345 related individuals clustered 
in 462 families. The family size ranged between 2 and 5 with an average of 2.9 
members. Of the families, 196 were control families, 243 had one affected case only, 21 
families included two cases and another 2 families had three cases. Data from these 
individuals were analysed at 695,193 autosomal SNPs. 
 
Population structure analysis 
To investigate the genetic structure in the data we performed principal component 
analysis (PCA) of unrelated individuals using EIGENSOFT version 3.0 (69) on a thinned 
set of SNPs (see Supplementary Material). Owing to the multicenter nature of our study 
we assessed the need to include principal components (PCs) as covariates in statistical 
tests of association to control for population stratification (70). This was done by using 
PLINK (42) to calculate the genome-wide distribution of the association test statistic in 
the unrelated individuals using different numbers of PCs as covariates. Possible inflation 
in the test statistic was measured by the genomic control parameter λ, which is the ratio 
of the median of the observed test statistic distribution to that of its expectation under 
the null hypothesis (71).  
 
Association analysis in our discovery sample 
A genome-wide association analysis was conducted with UNPHASED v3.1.4. (72), which 
allows a combined analysis of both families and unrelated individuals, thus increasing 
statistical power. UNPHASED calculates separately the transmitted and un-transmitted 
alleles in families as well as the allelic frequencies in unrelated patients and controls, 
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giving a combined odds ratio (OR), 95% confidence interval and P value. The analysis 
included three PCs as covariates. 
 
For SNPs showing association with psychosis in our data with P< 1 x 10-4, proxy SNPs 
were identified using the proxy report routine in PLINK (42). Only those SNPs that were 
in linkage disequilibrium (r2 ≥ 0.5) with and within 100 Kb distance from at least one 
such proxy SNP that showed association with psychosis with P< 1x10-2 were selected for 
the replication phase. These criteria reduced the possibility that the association signal 
was driven by an artifact at the most associated SNP. 
 
We attempted to replicate 44 SNPs included in the catalogue of published GWAS (73),  
accessed January 2012, for schizophrenia or bipolar disorder with P values less than 1 x 
10-7. These SNPs and the studies that identified them are listed in Table 1. If a reported 
SNP was not genotyped directly in our data, we used the 1000 Genomes Project (74) 
data to identify the best tag (highest r2) and orientated the haplotype to the risk allele 
so that the directions of the odds ratios were matched between our analysis and the 
previous studies. Where relevant information was not available the SNP was excluded 
from analysis. 
 
Related effects meta-analysis 
We attempted in silico replication with independent samples from the PGC and the 
SGENE+ consortia using both a fixed effects meta-analysis (42) and a Bayesian related 
effects approach (27). The Bayesian related effects model (Supplementary methods) 
was considered appropriate in this context since there are obvious sources of 
heterogeneity between the discovery and the replication datasets due to differing 
phenotype definitions and sample origins. To ensure that no samples were overlapping 
between the discovery and replication data sets, we used a subset of at least 13,000 
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SNPs to exclude 717 participants (51 cases, 642 controls, 24 relatives) from our primary 
study. Similarly, another 74 controls were excluded from the SGENE+ replication cohort. 
Only SGENE+ samples that were not part of the PGC study were included in our meta-
analyses. 
 
Polygenic score analysis 
A polygenic score analysis was conducted using a thinned (on the basis of linkage 
disequilibrium) panel of 113,774 SNPs from the PGC-Schizophrenia meta-analysis. Of 
these SNPs, 72,635 were available in our data and we further added suitable proxies for 
another 19,434 SNPs, which were identified through the program SNAP (75) to have r2> 
0.9 with the index SNP and to be within 500Kb distance. Of 4,835 samples passing the 
above described quality control filters we excluded 717 individuals that overlapped with 
the PGC sample and another 833 related participants. Therefore our polygenic analysis 
was based on a subset of 3,285 unrelated subjects comprising of 1,188 patients and 
2,097 controls. The polygenic score for each individual was calculated from the number 
of risk alleles they carried for each SNP, weighted by the log(OR) provided by the PGC, 
and summed across all the SNPs. Calculations were performed using the PLINK SNP 
scoring routine (42).  
 
We used logistic regression, with the three population structure principal components 
and the centre of origin of the samples as covariates, to test whether the polygenic 
scores were predictive of case-control status in our study. Following Purcell et al (26), 
we reported the proportion of the variance of disease risk in our sample (as measured 
by Nagelkerke’s pseudo-R2) that could be explained by the panel of SNPs. We examined 
the proportion of the variance explained by our data at various P-value thresholds for 
the PGC-schizophrenia SNP list (P< 0.01, 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5) (26, 43).  
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RESULTS 
The primary goal of our study was to use published genome wide association study data 
in schizophrenia and bipolar disorder to facilitate discovery in a new sample with a 
broad psychosis phenotype. Firstly, we examine previously published loci in our dataset. 
We then go on to present our discovery association data followed by replication in 
independent samples, using a novel meta-analysis approach. Finally, we report a 
polygenic score analysis testing if a panel of SNPs associated specifically with 
schizophrenia are predictive of the broader phenotype in our sample. 
 
Population structure 
Analysis of our data via PCA showed that the major components of the genetic variation 
capture the geographic origin of the samples (Supplementary figure 1). The first 
principal component separates samples from Northern Spain (Santander) from the rest 
of the sample. We found it necessary to include the first three PCs as covariates in order 
to control for the confounding effects of population structure even though this may 
reduce power to detect associations. The genomic control parameter, λ, was equal to 
1.030 and 1.374 with and without including the three PCs respectively. 
 
Replication of previously published loci in our dataset 
To ascertain the strength of association in our data at loci previously associated with 
schizophrenia and/or bipolar disorder, we systematically assessed the evidence at the 
SNPs most strongly correlated with the previously reported SNPs and their risk alleles 
(Table 1 and Figure 1) (12, 15, 21, 23, 24, 26, 28, 30, 33, 34, 37, 38, 66, 76-96). We 
observed evidence for association at several loci. These include multiple SNPs in the 
MHC region, most strongly at rs9272219 near HLA-DQA1. We also replicated association 
at MIR137, MCTP1, NRGN and CDC68. More generally, we observed a positive 
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correlation between previously reported effect sizes and those estimated here, most 
notably with schizophrenia associated loci where 19 out of the 24 loci had the same risk 
allele (one-sided P = 0.003). We note that this sign test remained significant (P < 0.05) 
after thinning to reduce correlation between SNPs and removing the SNPs within the 
MHC (see Supplementary Table 4). 
 
Association analysis in our discovery sample 
We did not identify any novel SNPs associated with psychosis as a broad phenotype with 
P< 1x10-7 from our data set. Figure 2 and supplementary figure 2 show respectively the 
quantile-quantile plots of the distribution of observed and expected P values and the 
Manhattan plot of all autosomal SNPs that passed quality control. 
 
Independent replication of our discovery data 
We selected 63 SNPs in 23 genomic regions (Supplementary Data) showing the 
strongest evidence for association in our discovery dataset (P< 1 x 10-4) and having at 
least one suitable proxy SNP also associated (see Methods). We then attempted in silico 
replication using the large independent (see Methods) datasets publicly available from 
the Psychiatric Genomics Consortium (51, 57, 97, 98) as well as with data provided by 
the SGENE+ Consortium (24, 25).  
 
All of the selected 63 SNPs were present in at least one of the replication datasets and 
53 SNPs were available in both collections giving a two-study independent replication 
dataset with 10,352 patients and 24,474 controls. By combining estimates of the 
logarithmic odds ratios weighted by their precision (i.e., inverse variance of the 
estimator) across discovery and replication cohorts, we conducted a three-study meta-
analysis with a total of 11,540 patients, 833 of their unaffected relatives and 26,571 
controls.  Table 2 contains the SNPs that in the replication data showed an effect in the 
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same direction (with one-sided P< 0.05) as in the discovery data set and had either 
combined (discovery plus replication) fixed effects P value < 10-3 or combined fixed 
effects or related effects Bayes factor > 100. Regional association plots of these SNPs 
are included in Figure 3 and forest plots are given in Supplementary figure 3. Full details 
of the replication meta-analyses are presented in Supplementary Data. 
 
Two out of five top regions in our discovery analysis, rs743393 (on chromosome 3) and 
rs968794 (on chromosome 7), showed effects in the same direction in the replication 
data with one-sided replication P values of 0.020 and 0.007, respectively. However, the 
combined fixed effects evidence of association at these loci is weak by the standards of 
GWAS (P values 7 x 10-4 and 8 x 10-5, and Bayes factors 25 and 200, respectively). Bayes 
factors from the related effects model (440 and 7400, respectively), which allow 
heterogeneity in effect size across studies, are larger than those from the fixed effect 
model, but still fail to provide convincing levels of evidence for these associations. See 
(66) for interpreting Bayes factors in the GWAS context. 
 
Polygenic score analysis 
We performed a polygenic score analysis using the SNPs associated with schizophrenia 
in the Psychiatric Genomics Consortium study. Logistic regression analyses showed 
significantly higher scores for patients than controls (P =5x10-14), and explained 
approximately 1.7% of Nagelkerke’s pseudo-variance in our sample. For additional 
results on the polygenic component, see Supplementary material and Supplementary 
Figure 4. 
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DISCUSSION 
 
Although extensive twin research has shown high heritability estimates ranging 
between 73-85% for schizophrenia, schizoaffective disorder and manic syndromes (99-
103), compared to other neuropsychiatric diseases, the search for psychosis 
susceptibility genes has not been straightforward (104-110). Several loci have now been 
convincingly identified and more are expected to be found through the Psychiatric 
Genomics Consortium, a large international collaboration undertaking mega-analyses of 
the available data (8, 12, 28). In this context, our sample with 4,835 participants has 
modest power to detect new variants unequivocally (111) and thus it is not that 
surprising that we did not identify convincing novel associations with a broad psychosis 
phenotype. For example, our data provide less than 10% power at type I error of 1x10-7 
for an allelic relative risk of 1.2 at a common SNP, and in practice power may be further 
reduced due to our broader disease phenotype and our use of principal component 
covariates to control for population structure. It has been estimated that for allelic odds 
ratios of 1.1 and 1.2 as many as 10,000 to over 20,000 subjects would be required to 
achieve 80% power at genome wide significance levels (112). We hope that our data set 
will be valuable in the future meta-analyses that are likely to identify further common 
variants for psychotic illnesses with convincing statistical evidence.  
 
The loci for which we found the best evidence of association, given our data and the 
independent replication samples from the Psychiatric Genomics and SGENE+ consortia, 
are reported in Table 2 and their regional association plots are in Figure 3. These include 
rs743393 located in chromosome 3, which is near the Integrin alpha 9 gene (ITGA9), 
thought to codify for a membrane glycoprotein that mediates cell-cell and cell-matrix 
adhesion (22). SNP rs968794 in chromosome 7 is close to the NDUFA4 gene coding for a 
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protein that is involved in the mitochondrial membrane respiratory chain (23). Finally, 
rs4761708 is located in a gene desert in chromosome 12 flanked by recombination 
hotspots. Limited information is available on the role of these genes and whether they 
are causal in increasing the risk of developing psychosis. Further data is required to 
confirm the associations and to inform on underlying disease mechanisms. 
 
While our sample was too small to identify new loci unequivocally, it had good power to 
replicate previously published signals with modest effects assuming they are consistent 
across psychosis phenotypes. The analysis of established schizophrenia loci shows that 
there is a trend for consistent association in our data (Figure 1). Also the polygenic score 
analysis showed that, compared to controls, our cases are enriched for alleles thought to 
convey risk for schizophrenia; the PGC’s panel of SNPs significantly predicted case-control 
status in our study and explained around 2% of the phenotypic variance in our sample. This 
is comparable to previously reported figures in other European case-control and family 
based populations (26, 43) and is consistent with a highly polygenic model of disease risk. 
Larger data sets are required to determine whether these signals are specific to only some 
of the sub-phenotypes of psychosis or are present across them.  
 
Schizophrenia and bipolar disorder are thought to be highly complex and polygenic, 
with potentially thousands of susceptibility genes of small effect and, particularly for 
schizophrenia, also with rare variants of larger effects (10, 14, 26, 52, 58, 107, 113-116). 
Previous GWAS have generally targeted a specific diagnostic category and the merit of 
analysing a psychosis spectrum is debatable. One of the challenges facing psychiatric 
genetics has been the heterogeneity of the diseases in question and studying a broader 
phenotype could exacerbate  this problem. However, as GWAS data accumulate there is 
growing evidence of genetic overlap between schizophrenia and bipolar disorder (8, 12, 
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28, 44, 46, 51, 55, 56, 58-60). Therefore, as well as examining narrowly defined diseases 
it is of use to undertake cross-disorder analyses. Our replication of established 
schizophrenia hits in a broadly defined psychosis sample and polygenic analyses support 
this view.  
 
Current benchmarks for establishing new associations usually insist on a combined 
discovery and replication P value of less than 5 x10-8 using a fixed effects meta-analysis, 
which is the correct summary of the overall statistical evidence when the true effect size 
is exactly the same across the studies. However, when the effect size may genuinely 
differ between the studies due to, for example, differences in phenotype definition, 
patterns of linkage disequilibrium or environmental contributions, it is appropriate to 
assess association evidence with a model that allows for heterogeneity. Here we have 
used a Bayesian related effects model that assumes that the effects between the 
studies are similar (e.g. highly correlated on the log odds scale) but not necessarily the 
same. A computational advantage of this model is that it only requires the study-wide 
summary statistics (effect size and its standard error) and therefore we believe that it 
will be useful in future meta-analyses of existing GWAS data sets, for example across 
neuropsychiatric diseases. 
 
In our study, we applied the related effects model to combine the discovery and 
replication results at 63 SNPs that had the most evidence in the discovery analysis. As 
expected, the related effects model assigns a higher probability than the fixed effects 
model to the event that these SNPs represent real associations (Supplementary Data). 
For any one SNP, this can be either because the association is a true-positive but 
heterogeneous and/or subject to a “winner’s curse” effect (117, 118), or because the 
association is a false-positive and appears heterogeneous due to a relatively strong 
discovery signal created by chance effects. Future studies are needed to determine 
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conclusively whether the SNPs reported in Table 2 and Figure 3 represent real 
associations. 
 
The scenario described here, where a discovery analysis of a particular phenotype in a 
small sample attempts to replicate putative associations in silico, in much larger meta-
analyses of similar phenotypes, is likely to become more common in human genetics as 
GWAS data accumulate. We note that stringent P value thresholds for combined 
discovery and replication meta-analysis make it challenging to identify new loci because 
loci with consistent effects across studies will have already been identified. Therefore in 
on-going genome-wide meta-analysis across related phenotypes, modelling effect 
heterogeneity where appropriate is arguably the most powerful approach to identify 
additional susceptibility loci.  
 
In conclusion, although no individual SNPs reached convincing evidence of association 
with psychosis, our data contribute to the international effort to produce a cohort large 
enough to investigate both the shared and separate genetic bases of multiple psychotic 
disorders. Our polygenic score analysis indicates that the PGC-derived panel of SNPs 
conveying risk specifically for schizophrenia is also predictive of case-control status in 
our data, explaining around 2% of the phenotypic variance. We advocate the use of 
related effects models in large meta-analyses for summarising the evidence for 
association across independent studies of related phenotypes. 
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Table 1: Evidence in our discovery data at loci previously reported to be associated with schizophrenia and/or bipolar disorder. 
Evidence for association at the best marker, as measured by correlation (r2) in the 1000 Genomes Project data (74), of previously implicated loci. Where 
the previously reported SNP is not typed in our data we oriented the haplotypes to estimate the odds ratio for the risk allele allowing a one sided 
comparison. One–sided P values < 0.05 (for replication with the same risk allele) are highlighted in bold font. SCZ: Schizophrenia, BPD: Bipolar Disorder. 
 
 
Chr Position 
(b36) 
Genes SNP 
risk allele 
Odds 
ratio 
Phenot. Previous studies Best tag r2 
1000 
genomes 
Frequency P value 
(two-sided) 
Odds ratio 
(95% CI) 
1 98502934 MIR137 rs1625579-T 1.12 SCZ (12) rs1782810 0.975 0.8034 0.0641257 1.14 (0.99-1.31) 
1 167903079 BRP44, DCAF6 rs10489202-A 1.23 SCZ (21) rs10489202 1.000 0.2312 0.310317 1.07 (0.94-1.21) 
1 243608967 - rs6703335-G 1.09 SCZ (12) rs6703335 1.000 0.4324 0.476216 0.96 (0.86-1.07) 
2 58222928 VRK2 rs2312147-C 1.09 SCZ (24, 76) rs1518395 1.000 0.6172 0.740698 0.98 (0.88-1.1) 
2 193984621 PCGEM1 rs17662626-A 1.2 SCZ (12) rs17666314 0.633 0.942 0.810016 1.03 (0.82-1.29) 
3 36862980 - rs4624519-T 1.09 SCZ (12) rs4624519 1.000 0.6264 0.709072 1.02 (0.91-1.14) 
3 52821011 ITIH1, NEK4 rs1042779-A 1.19 BPD (38, 119) rs1042779 1.000 0.6237 0.357295 1.05 (0.94-1.18) 
3 52855229 ITIH3, ITIH4 rs2239547-T 1.1 SCZ (12) rs1573815 0.786 0.7678 0.283078 1.07 (0.94-1.22) 
3 180550702 FXR1 rs6782299-T 1.1 SCZ (26) rs6782299 1.000 0.7294 0.822086 1.01 (0.9-1.14) 
4 103457418 NFKB1 rs230529-T 1.45 SCZ (78) rs230529 1.000 0.3895 0.363959 1.05 (0.94-1.17) 
5 94154588 MCTP1 rs17418283-C 1.21 BPD (38) rs255339 0.834 0.2968 0.0838988 1.11 (0.99-1.25) 
6 27143883 MHC rs13194053-T 1.22 SCZ (23, 26) rs7745603 0.866 0.7697 0.103731 1.11 (0.98-1.27) 
6 27248931 MHC rs6932590-T 1.16 SCZ (24, 26, 79, 80) rs6938200 0.874 0.7947 0.219974 1.09 (0.95-1.25) 
6 28227604 MHC,NKAPL rs1635-G 1.28 SCZ (81) rs2299030 0.909 0.03693 0.265435 1.16 (0.89-1.52) 
6 30174131 MHC,TRIM26 rs2021722-C 1.15 SCZ (12) rs2517611 1.000 0.8058 0.418896 0.95 (0.83-1.08) 
6 32172993 MHC, NOTCH4 rs3131296-G 1.19 SCZ (24, 80) rs2071278 1.000 0.8534 0.61264 1.04 (0.89-1.22) 
6 32602269 MHC,HLA-DQA1 rs9272219-G 1.14 SCZ (23) rs9272219 1.000 0.7105 0.0740771 1.12 (0.99-1.26) 
6 89732101 GABRR1 rs12201676-C 1.31 SCZ & BPD (82) rs12201676 1.000 0.2452 0.211557 1.08 (0.96-1.22) 
7 145959243 CNTNAP2 rs802568-C 2.03 SCZ & BPD (82) rs802568 1.000 0.02746 0.197092 1.22 (0.9-1.65) 
7 156048649 LOC393076 rs10949808-T 1.27 SCZ & BPD (82) rs10949808 1.000 0.397 0.224947 1.07 (0.96-1.19) 
8 4180844 CSMD1 rs10503253-A 1.16 SCZ (12) rs10103330 1.000 0.1993 0.807814 1.02 (0.89-1.16) 
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8 38031345 LSM1, WHSC1L1 rs16887244-A 1.19 SCZ (21) rs16887244 1.000 0.7614 0.436771 1.05 (0.93-1.19) 
8 58840924 FAM110B rs1992045-T 1.56 SCZ & BPD (82) rs1992045 1.000 0.07363 0.125349 0.85 (0.69-1.05) 
8 89760311 MMP16 rs7004633-A 1.11 SCZ (12, 83) rs7005110 1.000 0.1925 0.914021 0.99 (0.87-1.14) 
9 121359286 ASTN2 rs11789399-G 1.29 SCZ & BPD (82) rs11789399 1.000 0.4962 0.415783 0.96 (0.86-1.06) 
10 62179812 ANK3 rs10994336-T 1.45 BPD (33, 38, 84-87) rs3808943 0.858 0.05389 0.209758 0.85 (0.66-1.1) 
10 62279124 ANK3 rs10994397-T 1.22 BPD (28) rs3808943 0.858 0.05389 0.209758 0.85 (0.66-1.1) 
10 104775908 CNNM2 rs7914558-G 1.22 SCZ (12, 88) rs10509757 1.000 0.5927 0.131729 1.09 (0.98-1.21) 
10 104906211 NT5C2 rs11191580-T 1.2 SCZ (12, 88) rs11191580 1.000 0.9169 0.912034 1.01 (0.83-1.23) 
11 17160148 - rs4356203-G 1.09 SCZ (12) rs4356203 1.000 0.4236 0.342312 0.95 (0.85-1.06) 
11 66551002 Multiple rs10896135-G 1.12 BPD (28) rs4930390 1.000 0.2557 0.901194 0.99 (0.88-1.12) 
11 79077193 ODZ4 rs12576775-G 1.14 BPD (28) rs7932890 1.000 0.1737 0.259849 1.08 (0.94-1.24) 
11 98125404 CNTN5 rs2509843-C 1.27 SCZ & BPD (82) rs2848547 1.000 0.3711 0.400322 0.95 (0.86-1.06) 
11 124606285 NRGN rs12807809-T 1.15 SCZ (24, 80, 89) rs1939214 0.972 0.8282 0.0051205 1.23 (1.06-1.43) 
12 2345295 CACNA1C rs1006737-A 1.18 SCZ & BPD (15, 33, 37, 38, 
90) 
rs1006737 1.000 0.3265 0.353821 1.05 (0.94-1.18) 
12 2419896 CANCNA1C rs4765913-A 1.14 BPD (28) rs4765914 0.935 0.8061 0.432068 0.95 (0.83-1.08) 
13 42653437 DGKH rs1012053-A 1.59 BPD (91-93) rs1170188 0.806 0.8133 0.26017 1.08 (0.94-1.24) 
13 106651661 DAOA rs4996815-C 1.28 SCZ & BPD (82) rs4996815 1.000 0.3576 0.737436 1.02 (0.91-1.14) 
15 38995491 Multiple rs12899449-A 1.2 BPD (33) rs12899449 1.000 0.7063 0.441365 1.05 (0.93-1.18) 
16 23634026 Multiple rs420259-A 2.08 BPD (34, 66, 94, 95) rs420259 1.000 0.7306 0.517701 0.96 (0.85-1.08) 
18 52752017 CCDC68 rs12966547-G 1.4 SCZ (12) rs11874716 1.000 0.567 0.0379359 1.12 (1.01-1.25) 
18 53058238 TCF4 rs17594526-T 1.44 SCZ (26) rs17594526 1.000 0.0321 0.915797 1.02 (0.76-1.36) 
19 19361735 NCAN rs1064395-A 1.17 SCZ &BPD (30, 96) rs1064395 1.000 0.1639 0.543254 0.96 (0.83-1.1) 
20 19852503 RIN2 rs6046396-G 1.28 SCZ & BPD (82) rs6046396 1.000 0.3015 0.57124 1.03 (0.92-1.16) 
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Table 2: Loci where we found the strongest evidence of association. 
Evidence of association across the discovery sample and the PCG and SGENE replication collections as also shown as a forest plot in Supplementary figure 3. 
We report P values, odds ratios (and 95% confidence intervals) for these cohorts and the combined evidence (using an inverse variance weighted fixed effects 
approach). We also show the log10 Bayes factor (BF) for models assuming effects to be either the same (fixed) or related (allowing heterogeneity). Note that 
the discovery sample odds ratios and P values presented in this table are based on a sub-set of our sample that did not overlap with the replication cohorts, 
therefore the P values may vary from those presented in supplementary figure 2, which includes all our discovery dataset. 
 
 
 
 
 
Chr. 
SNP 
(risk allele) 
Position 
(Build 36) 
Discovery P 
Odds ratio (95% CI) 
Replication P 
Odds ratio (95% CI) 
Combined P 
Odds ratio (95% CI) 
log10BF 
same 
log10BF 
related 
3 rs743393-C 37718972 9.40E-06 0.039 7.40E-04 1.43 2.64 
   1.301 (1.157 - 1.462) 1.043 (1.002 - 1.085) 1.067 (1.028 - 1.108)   
7 rs968794-A 10856010 8.30E-07 0.014 8.40E-05 2.3 3.87 
   1.324 (1.184 - 1.480) 1.050 (1.010 - 1.091) 1.076 (1.037 - 1.116)   
12 rs4761708-C 92276217 1.40E-04 0.024 6.40E-04 1.56 2.18 
   1.291 (1.130 - 1.476) 1.058 (1.007 -1.110) 1.083 (1.034 - 1.133)   
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FIGURE LEGENDS 
 
Figure 1: Replication of previously published associated schizophrenia (SZ) and bipolar disorder 
(BP) loci.   
Reported odds ratios from the literature (x axis) plotted against the odds ratios estimated from our 
data as listed in Table 1 (y axis). The dotted line indicates an odds ratio of 1 in our data. Points above 
the line indicate the same direction of effect in previous studies and our data. Black circles indicate 
SNPs that replicate (P one-sided < 0.05) in our study. Triangles denote SNPs within the MHC region. 
Sign tests for an enrichment of effect in the same direction are presented for loci previously 
associated with schizophrenia, bipolar disorder or both. Further details on the sign tests are 
available in Supplementary Table 4. 
 
Figure 2: Quantile-quantile plots of the distribution of observed and expected P value at all 
autosomal SNPs passing quality control. The genomic control lambda value was 1.03. This 
represents analyses conducted on our entire discovery sample (n=4835).  
 
 
Figure 3: Regional association plots for the three SNPs reported in Table 2.  
The plots show the evidence of association in our discovery data at genotyped SNPs. The SNP listed in 
Table 2 is indicated with a diamond and flanking SNPs (circles) are coloured according to their 
correlations (r2) with this SNP measured in HapMap. 
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